Allogeneic Hematopoietic Cell Transplantation as Curative Therapy for Patients with Non-Hodgkin Lymphoma: Increasingly Successful Application to Older Patients

Biology of Blood and Marrow Transplantation

Volumn 22, Issue 9, 2016, Pages 1543-1551

  Fenske, Timothy S ^a   Hamadani, Mehdi ^a,b   Cohen, Jonathon B ^c   Costa, Luciano J ^d   Kahl, Brad S ^e   Evens, Andrew M ^f   Hamlin, Paul A ^g   Lazarus, Hillard M ^h   Petersdorf, Effie ⁱ   Bredeson, Christopher ^j  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

^b CENTER FOR INTERNATIONAL BLOOD AND MARROW TRANSPLANT RESEARCH   (United States)

^c EMORY UNIVERSITY   (United States)

^d Heerskink School of Medicine   (United States)

^e WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f TUFTS MEDICAL CENTER   (United States)

^g WEILL CORNELL MEDICAL COLLEGE   (United States)

^h CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

ⁱ UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^j OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

more..

Author keywords

Allogeneic hematopoietic cell transplantation; Elderly; Non Hodgkin lymphoma; Reduced intensity conditioning

Indexed keywords

ANTINEOPLASTIC AGENT;

AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER REGRESSION; CANCER THERAPY; FOLLICULAR LYMPHOMA; HUMAN; LARGE CELL LYMPHOMA; MANTLE CELL LYMPHOMA; MULTICENTER STUDY (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); REVIEW; TREATMENT FAILURE; ALLOTRANSPLANTATION; DIFFUSE LARGE B CELL LYMPHOMA; DONOR SELECTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; MIDDLE AGED; NONHODGKIN LYMPHOMA; PROCEDURES; TRENDS;

AGED; DONOR SELECTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LYMPHOMA, FOLLICULAR; LYMPHOMA, LARGE B-CELL, DIFFUSE; LYMPHOMA, MANTLE-CELL; LYMPHOMA, NON-HODGKIN; MIDDLE AGED; TRANSPLANTATION, HOMOLOGOUS;

EID: 84991255774     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2016.04.019     Document Type: Review

References (85)

1. 1 Zhou, Z., Sehn, L.H., Rademaker, A.W., et al. An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era. Blood 123 (2014), 837–842.
2. 2 Coiffier, B., Lepage, E., Briere, J., et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 346 (2002), 235–242.
3. 3 Rosenwald, A., Wright, G., Chan, W.C., et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med 346 (2002), 1937–1947.
4. 4 Hans, C.P., Weisenburger, D.D., Greiner, T.C., et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 103 (2004), 275–282.
5. 5 Cheah, C.Y., Oki, Y., Westin, J.R., Turturro, F., A clinician's guide to double-hit lymphomas. Br J Haematol 168 (2015), 784–795.
6. 6 Petrich, A.M., Gandhi, M., Jovanovic, B., et al. Impact of induction regimen and stem cell transplantation on outcomes in double-hit lymphoma: a multicenter retrospective analysis. Blood 124 (2014), 2354–2361.
7. 7 Philip, T., Guglielmi, C., Hagenbeek, A., et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med 333 (1995), 1540–1545.
8. 8 Hamadani, M., Hari, P.N., Zhang, Y., et al. Early failure of frontline rituximab-containing chemo-immunotherapy in diffuse large B cell lymphoma does not predict futility of autologous hematopoietic cell transplantation. Biol Blood Marrow Transplant 20 (2014), 1729–1736.
9. 9 Gisselbrecht, C., Glass, B., Mounier, N., et al. Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era. J Clin Oncol 28 (2010), 4184–4190.
10. 10 Vose, J.M., Carter, S., Burns, L.J., et al. Phase III randomized study of rituximab/carmustine, etoposide, cytarabine, and melphalan (BEAM) compared with iodine-131 tositumomab/BEAM with autologous hematopoietic cell transplantation for relapsed diffuse large B-cell lymphoma: results from the BMT CTN 0401 trial. J Clin Oncol 31 (2013), 1662–1668.
11. 11 Gisselbrecht, C., Schmitz, N., Mounier, N., et al. Rituximab maintenance therapy after autologous stem-cell transplantation in patients with relapsed CD20(+) diffuse large B-cell lymphoma: final analysis of the collaborative trial in relapsed aggressive lymphoma. J Clin Oncol 30 (2012), 4462–4469.
12. 12 Thomson, K.J., Morris, E.C., Bloor, A., et al. Favorable long-term survival after reduced-intensity allogeneic transplantation for multiple-relapse aggressive non-Hodgkin's lymphoma. J Clin Oncol 27 (2009), 426–432.
13. 13 Sirvent, A., Dhedin, N., Michallet, M., et al. Low nonrelapse mortality and prolonged long-term survival after reduced-intensity allogeneic stem cell transplantation for relapsed or refractory diffuse large B cell lymphoma: report of the Société Française de Greffe de Moelle et de Thérapie Cellulaire. Biol Blood Marrow Transplant 16 (2010), 78–85.
14. 14 Lazarus, H.M., Zhang, M.J., Carreras, J., et al. A comparison of HLA-identical sibling allogeneic versus autologous transplantation for diffuse large B cell lymphoma: a report from the CIBMTR. Biol Blood Marrow Transplant 16 (2010), 35–45.
15. 15 van Kampen, R.J., Canals, C., Schouten, H.C., et al. Allogeneic stem-cell transplantation as salvage therapy for patients with diffuse large B-cell non-Hodgkin's lymphoma relapsing after an autologous stem-cell transplantation: an analysis of the European Group for Blood and Marrow Transplantation Registry. J Clin Oncol 29 (2011), 1342–1348.
16. 16 Rigacci, L., Puccini, B., Dodero, A., et al. Allogeneic hematopoietic stem cell transplantation in patients with diffuse large B cell lymphoma relapsed after autologous stem cell transplantation: a GITMO study. Ann Hematol 91 (2012), 931–939.
17. 17 Bacher, U., Klyuchnikov, E., Le-Rademacher, J., et al. Conditioning regimens for allotransplants for diffuse large B-cell lymphoma: myeloablative or reduced intensity?. Blood 120 (2012), 4256–4262.
18. 18 Hamadani, M., Saber, W., Ahn, K.W., et al. Impact of pretransplantation conditioning regimens on outcomes of allogeneic transplantation for chemotherapy-unresponsive diffuse large B cell lymphoma and grade III follicular lymphoma. Biol Blood Marrow Transplant 19 (2013), 746–753.
19. 19 Fenske, T.S., Ahn, K.W., Graff, T.M., et al. Allogeneic transplantation provides durable remission in a subset of DLBCL patients relapsing after autologous transplantation. Br J Haematol, 2016, 10.1016/j.bbmt.2016.04.019 [Epub ahead of print].
20. 20 Klyuchnikov, E., Bacher, U., Kroll, T., et al. Allogeneic hematopoietic cell transplantation for diffuse large B cell lymphoma: who, when and how?. Bone Marrow Transplant 49 (2014), 1–7.
21. 21 Bishop, M.R., Dean, R.M., Steinberg, S.M., et al. Clinical evidence of a graft-versus-lymphoma effect against relapsed diffuse large B-cell lymphoma after allogeneic hematopoietic stem-cell transplantation. Ann Oncol 19 (2008), 1935–1940.
22. 22 McClune, B.L., Ahn, K.W., Wang, H.L., et al. Allotransplantation for patients age ≥40 years with non-Hodgkin lymphoma: encouraging progression-free survival. Biol Blood Marrow Transplant 20 (2014), 960–968.
23. 23 Kim, J.W., Kim, S.W., Tada, K., et al. Allogeneic stem cell transplantation in patients with de novo diffuse large B-cell lymphoma who experienced relapse or progression after autologous stem cell transplantation: a Korea-Japan collaborative study. Ann Hematol 93 (2014), 1345–1351.
24. 24 Vose, J.M., Bierman, P.J., Anderson, J.R., et al. Progressive disease after high-dose therapy and autologous transplantation for lymphoid malignancy: clinical course and patient follow-up. Blood 80 (1992), 2142–2148.
25. 25 Nagle, S.J., Woo, K., Schuster, S.J., et al. Outcomes of patients with relapsed/refractory diffuse large B-cell lymphoma with progression of lymphoma after autologous stem cell transplantation in the rituximab era. Am J Hematol 88 (2013), 890–894.
26. 26 Costa, L.J., Micallef, I.N., Inwards, D.J., et al. Time of relapse after initial therapy significantly adds to the prognostic value of the IPI-R in patients with relapsed DLBCL undergoing autologous stem cell transplantation. Bone Marrow Transplant 41 (2008), 715–720.
27. 27 Solal-Céligny, P., Roy, P., Colombat, P., et al. Follicular lymphoma international prognostic index. Blood 104 (2004), 1258–1265.
28. 28 Brice, P., Bastion, Y., Lepage, E., et al. Comparison in low-tumor-burden follicular lymphomas between an initial no-treatment policy, prednimustine, or interferon alfa: a randomized study from the Groupe d'Etude des Lymphomes Folliculaires. Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol 15 (1997), 1110–1117.
29. 29 Kahl, B.S., Hong, F., Williams, M.E., et al. Rituximab extended schedule or re-treatment trial for low-tumor burden follicular lymphoma: Eastern Cooperative Oncology Group protocol E4402. J Clin Oncol 32 (2014), 3096–3102.
30. 30 Rummel, M.J., Niederle, N., Maschmeyer, G., et al. Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial. Lancet 381 (2013), 1203–1210.
31. 31 Freedman, A., Follicular lymphoma: 2014 update on diagnosis and management. Am J Hematol 89 (2014), 429–436.
32. 32 Casulo, C., Byrtek, M., Dawson, K.L., et al. Early relapse of follicular lymphoma after rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone defines patients at high risk for death: an analysis from the National LymphoCare Study. J Clin Oncol 33 (2015), 2516–2522.
33. 33 Lenz, G., Dreyling, M., Schiegnitz, E., et al. Myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission prolongs progression-free survival in follicular lymphoma: results of a prospective, randomized trial of the German Low-Grade Lymphoma Study Group. Blood 104 (2004), 2667–2674.
34. 34 Deconinck, E., Foussard, C., Milpied, N., et al. High-dose therapy followed by autologous purged stem-cell transplantation and doxorubicin-based chemotherapy in patients with advanced follicular lymphoma: a randomized multicenter study by GOELAMS. Blood 105 (2005), 3817–3823.
35. 35 Sebban, C., Mounier, N., Brousse, N., et al. Standard chemotherapy with interferon compared with CHOP followed by high-dose therapy with autologous stem cell transplantation in untreated patients with advanced follicular lymphoma: the GELF-94 randomized study from the Groupe d'Etude des Lymphomes de l'Adulte (GELA). Blood 108 (2006), 2540–2544.
36. 36 Ladetto, M., De Marco, F., Benedetti, F., et al. Prospective, multicenter randomized GITMO/IIL trial comparing intensive (R-HDS) versus conventional (CHOP-R) chemoimmunotherapy in high-risk follicular lymphoma at diagnosis: the superior disease control of R-HDS does not translate into an overall survival advantage. Blood 111 (2008), 4004–4013.
37. 37 Schouten, H.C., Qian, W., Kvaloy, S., et al. High-dose therapy improves progression-free survival and survival in relapsed follicular non-Hodgkin's lymphoma: results from the randomized European CUP trial. J Clin Oncol 21 (2003), 3918–3927.
38. 38 Sebban, C., Brice, P., Delarue, R., et al. Impact of rituximab and/or high-dose therapy with autotransplant at time of relapse in patients with follicular lymphoma: a GELA study. J Clin Oncol 26 (2008), 3614–3620.
39. 39 Hamadani, M., Reappraising the role of autologous transplantation for indolent B-cell lymphomas in the chemoimmunotherapy era: is it still relevant?. Bone Marrow Transplant 48 (2013), 1013–1021.
40. 40 Rezvani, A.R., Storer, B., Maris, M., et al. Nonmyeloablative allogeneic hematopoietic cell transplantation in relapsed, refractory, and transformed indolent non-Hodgkin's lymphoma. J Clin Oncol 26 (2008), 211–217.
41. 41 Hari, P., Carreras, J., Zhang, M.J., et al. Allogeneic transplants in follicular lymphoma: higher risk of disease progression after reduced-intensity compared to myeloablative conditioning. Biol Blood Marrow Transplant 14 (2008), 236–245.
42. 42 Piñana, J.L., Martino, R., Gayoso, J., et al. Reduced-intensity conditioning HLA identical sibling donor allogeneic stem cell transplantation for patients with follicular lymphoma: long-term follow-up from two prospective multicenter trials. Haematologica 95 (2010), 1176–1182.
43. 43 Thomson, K.J., Morris, E.C., Milligan, D., et al. T-cell-depleted reduced-intensity transplantation followed by donor leukocyte infusions to promote graft-versus-lymphoma activity results in excellent long-term survival in patients with multiply relapsed follicular lymphoma. J Clin Oncol 28 (2010), 3695–3700.
44. 44 Khouri, I.F., Saliba, R.M., Erwin, W.D., et al. Nonmyeloablative allogeneic transplantation with or without yttrium-90 ibritumomab tiuxetan is potentially curative for relapsed follicular lymphoma: 12-year results. Blood 119 (2012), 6373–6378.
45. 45 Evens, A.M., Vanderplas, A., LaCasce, A.S., et al. Stem cell transplantation for follicular lymphoma relapsed/refractory after prior rituximab: a comprehensive analysis from the NCCN lymphoma outcomes project. Cancer 119 (2013), 3662–3671.
46. 46 Robinson, S.P., Canals, C., Luang, J.J., et al. The outcome of reduced-intensity allogeneic stem cell transplantation and autologous stem cell transplantation when performed as a first transplant strategy in relapsed follicular lymphoma: an analysis from the Lymphoma Working Party of the EBMT. Bone Marrow Transplant 48 (2013), 1409–1414.
47. 47 Klyuchnikov, E., Bacher, U., Kröger, N.M., et al. Reduced-intensity allografting as first transplantation approach in relapsed/refractory grades one and two follicular lymphoma provides improved outcomes in long-term survivors. Biol Blood Marrow Transplant 21 (2015), 2091–2099.
48. 48 Klyuchnikov, E., Bacher, U., Woo Ahn, K., et al. Long-term survival outcomes of reduced-intensity allogeneic or autologous transplantation in relapsed grade 3 follicular lymphoma. Bone Marrow Transplant 51 (2016), 58–66.
49. 49 Yano, S., Mori, T., Kanda, Y., et al. Favorable survival after allogeneic stem cell transplantation with reduced-intensity conditioning regimens for relapsed/refractory follicular lymphoma. Bone Marrow Transplant 50 (2015), 1299–1305.
50. 50 Shea, T., Johnson, J., Westervelt, P., et al. Reduced-intensity allogeneic transplantation provides high event-free and overall survival in patients with advanced indolent B cell malignancies: CALGB 109901. Biol Blood Marrow Transplant 17 (2011), 1395–1403.
51. 51 Khouri, I.F., McLaughlin, P., Saliba, R.M., et al. Eight-year experience with allogeneic stem cell transplantation for relapsed follicular lymphoma after nonmyeloablative conditioning with fludarabine, cyclophosphamide, and rituximab. Blood 111 (2008), 5530–5536.
52. 52 Lunning, M.A., Migliacci, J.C., Hilden, P., et al. The potential benefit of allogeneic over autologous transplantation in patients with very early relapsed and refractory follicular lymphoma with prior remission duration of ≤12 months. Br J Haematol 173 (2016), 260–264.
53. 53 Vose, J.M., Mantle cell lymphoma: 2015 update on diagnosis, risk-stratification, and clinical management. Am J Hematol 90 (2015), 739–745.
54. 54 Hoster, E., Dreyling, M., Klapper, W., et al. A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma. Blood 111 (2008), 558–565.
55. 55 Geisler, C.H., Kolstad, A., Laurell, A., et al. The Mantle Cell Lymphoma International Prognostic Index (MIPI) is superior to the International Prognostic Index (IPI) in predicting survival following intensive first-line immunochemotherapy and autologous stem cell transplantation (ASCT). Blood 115 (2010), 1530–1533.
56. 56 Lenz, G., Dreyling, M., Hoster, E., et al. Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG). J Clin Oncol 23 (2005), 1984–1992.
57. 57 Robak, T., Huang, H., Jin, J., et al. Bortezomib-based therapy for newly diagnosed mantle-cell lymphoma. N Engl J Med 372 (2015), 944–953.
58. 58 Flinn, I.W., van der Jagt, R., Kahl, B.S., et al. Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study. Blood 123 (2014), 2944–2952.
59. 59 Ruan, J., Martin, P., Shah, B., et al. Lenalidomide plus rituximab as initial treatment for mantle-cell lymphoma. N Engl J Med 373 (2015), 1835–1844.
60. 60 Romaguera, J.E., Fayad, L.E., Feng, L., et al. Ten-year follow-up after intense chemoimmunotherapy with rituximab-hyperCVAD alternating with rituximab-high dose methotrexate/cytarabine (R-MA) and without stem cell transplantation in patients with untreated aggressive mantle cell lymphoma. Br J Haematol 150 (2010), 200–208.
61. 61 Merli, F., Luminari, S., Ilariucci, F., et al. Rituximab plus hyperCVAD alternating with high dose cytarabine and methotrexate for the initial treatment of patients with mantle cell lymphoma, a multicentre trial from Gruppo Italiano Studio Linfomi. Br J Haematol 156 (2012), 346–353.
62. 62 Bernstein, S.H., Epner, E., Unger, J.M., et al. A phase II multicenter trial of hyperCVAD MTX/Ara-C and rituximab in patients with previously untreated mantle cell lymphoma; SWOG 0213. Annals of Oncology 24 (2013), 1587–1593.
63. 63 Kenkre, V.P., Long, W.L., Eickhoff, J.C., et al. Maintenance rituximab following induction chemoimmunotherapy for mantle cell lymphoma: long-term follow-up of a pilot study from the Wisconsin Oncology Network. Leuk Lymphoma 52 (2011), 1675–1680.
64. 64 Kluin-Nelemans, H.C., Hoster, E., Hermine, O., et al. Treatment of older patients with mantle-cell lymphoma. N Engl J Med 367 (2012), 520–531.
65. 65 Dreyling, M., Lenz, G., Hoster, E., et al. Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma: results of a prospective randomized trial of the European MCL Network. Blood 105 (2005), 2677–2684.
66. 66 Geisler, C.H., Kolstad, A., Laurell, A., et al. Nordic MCL2 trial update: six-year follow-up after intensive immunochemotherapy for untreated mantle cell lymphoma followed by BEAM or BEAC + autologous stem-cell support: still very long survival but late relapses do occur. Br J Haematol 158 (2012), 355–362.
67. 67 Damon, L.E., Johnson, J.L., Niedzwiecki, D., et al. Immunochemotherapy and autologous stem-cell transplantation for untreated patients with mantle-cell lymphoma: CALGB 59909. J Clin Oncol 27 (2009), 6101–6108.
68. 68 Tam, C.S., Bassett, R., Ledesma, C., et al. Mature results of the M.D. Anderson Cancer Center risk-adapted transplantation strategy in mantle cell lymphoma. Blood 113 (2009), 4144–4152.
69. 69 Delarue, R., Haioun, C., Ribrag, V., et al. CHOP and DHAP plus rituximab followed by autologous stem cell transplantation in mantle cell lymphoma: a phase 2 study from the Groupe d'Etude des Lymphomes de l'Adulte. Blood 121 (2013), 48–53.
70. 70 Hermine, O., Hoster, E., Walewski, J., et al. Alternating courses of 3× CHOP and 3× DHAP plus rituximab, followed by a high-dose ARA-C–containing myeloablative regimen and autologous stem cell transplantation (ASCT) increases overall survival when compared to 6 courses of CHOP plus rituximab followed by myeloablative radiochemotherapy and ASCT in mantle cell lymphoma: final analysis of the MCL Younger Trial of the European Mantle Cell Lymphoma Network (MCL net). ASH abstract. Blood, 120(Suppl), 2012, 151.
71. 71 Kolstad, A., Laurell, A., Jerkeman, M., et al. Nordic MCL3 study: 90Y-ibritumomab-tiuxetan added to BEAM/C in non-CR patients before transplant in mantle cell lymphoma. Blood 123 (2014), 2953–2959.
72. 72 Fenske, T.S., Zhang, M.J., Carreras, J., et al. Autologous or reduced-intensity conditioning allogeneic hematopoietic cell transplantation for chemotherapy-sensitive mantle-cell lymphoma: analysis of transplantation timing and modality. J Clin Oncol 32 (2014), 273–281.
73. 73 Cowan, A.J., Stevenson, P.A., Cassaday, R.D., et al. Pretransplantation minimal residual disease predicts survival in patients with mantle cell lymphoma undergoing autologous stem cell transplantation in complete remission. Biol Blood Marrow Transplant 22 (2016), 380–385.
74. 74 Budde, L.E., Guthrie, K.A., Till, B.G., et al. Mantle cell lymphoma International Prognostic Index but not pretransplantation induction regimen predicts survival for patients with mantle-cell lymphoma receiving high-dose therapy and autologous stem-cell transplantation. J Clin Oncol 29 (2011), 3023–3029.
75. 75 Vandenberghe, E., Ruiz de Elvira, C., Loberiza, F.R., et al. Outcome of autologous transplantation for mantle cell lymphoma: a study by the European Blood and Bone Marrow Transplant and Autologous Blood and Marrow Transplant Registries. Br J Haematol 120 (2003), 793–800.
76. 76 Cassaday, R.D., Guthrie, K.A., Budde, E.L., et al. Specific features identify patients with relapsed or refractory mantle cell lymphoma benefitting from autologous hematopoietic cell transplantation. Biol Blood Marrow Transplant 19 (2013), 1403–1406.
77. 77 Maris, M.B., Sandmaier, B.M., Storer, B.E., et al. Allogeneic hematopoietic cell transplantation after fludarabine and 2 Gy total body irradiation for relapsed and refractory mantle cell lymphoma. Blood 104 (2004), 3535–3542.
78. 78 Cook, G., Smith, G.M., Kirkland, K., et al. Outcome following reduced-intensity allogeneic stem cell transplantation (RIC alloSCT) for relapsed and refractory mantle cell lymphoma (MCL): a study of the British Society for Blood and Marrow Transplantation. Biol Blood Marrow Transplant 16 (2010), 1419–1427.
79. 79 Le Gouill, S., Kröger, N., Dhedin, N., et al. Reduced-intensity conditioning allogeneic stem cell transplantation for relapsed/refractory mantle cell lymphoma: a multicenter experience. Ann Oncol 23 (2012), 2695–2703.
80. 80 Hamadani, M., Saber, W., Ahn, K.W., et al. Allogeneic hematopoietic cell transplantation for chemotherapy-unresponsive mantle cell lymphoma: a cohort analysis from the Center for International Blood and Marrow Transplant Research. Biol Blood Marrow Transplant 19 (2013), 625–631.
81. 81 Krüger, W.H., Hirt, C., Basara, N., et al. Allogeneic stem cell transplantation for mantle cell lymphoma: final report from the prospective trials of the East German Study Group Haematology/Oncology (OSHO). Ann Hematol 93 (2014), 1587–1597.
82. 82 Kanate, A.S., Mussetti, A., Kharfan-Dabaja, M.A., et al. Reduced-intensity transplantation for lymphomas using haploidentical related donors versus HLA-matched unrelated donors. Blood 127 (2016), 938–947.
83. 83 Bachanova, V., Burns, L.J., Wang, T., et al. Alternative donors extend transplantation for patients with lymphoma who lack an HLA matched donor. Bone Marrow Transplant 50 (2015), 197–203.
84. 84 Kasamon, Y.L., Bolaños-Meade, J., Prince, G.T., et al. Outcomes of nonmyeloablative HLA-haploidentical blood or marrow transplantation with high-dose post-transplantation cyclophosphamide in older adults. J Clin Oncol 33 (2015), 3152–3161.
85. 85 Tomblyn, M.R., Ewell, M., Bredeson, C., et al. Autologous versus reduced-intensity allogeneic hematopoietic cell transplantation for patients with chemosensitive follicular non-Hodgkin lymphoma beyond first complete response or first partial response. Biol Blood Marrow Transplant 17 (2011), 1051–1057.